title: Delta12-Prostaglandin J2 inhibits the ubiquitin hydrolase UCH-L1 and elicits ubiquitin-protein aggregation without proteasome inhibition.
abstract: To investigate molecular mechanisms linking inflammation with neurodegeneration, we treated neuronal cultures with prostaglandins (PGs), which are mediators of inflammation. PGA1, D2, J2, and Delta12-PGJ2, but not PGE2, reduced the viability and raised the levels of ubiquitinated proteins in the neuronal cells. PGJ2 and its metabolite, Delta12-PGJ2, were the most potent of the four neurotoxic PGs tested in inducing both effects. To address the mechanism by which these agents lead to the accumulation of ubiquitinated proteins, we tested their effects on neuronal ubiquitin hydrolases UCH-L1 and UCH-L3 as well as on proteasome activity. Notably, Delta12-PGJ2 inhibited the activities of UCH-L1 (K(i) approximately 3.5 microM) and UCH-L3 (K(i) approximately 8.1 microM) without affecting proteasome activity. Intracellular aggregates containing ubiquitinated proteins were detected in Delta12-PGJ2-treated cells, indicating that these aggregates can form independently of proteasome inhibition. In conclusion, impairment of ubiquitin hydrolase activity, such as triggered by Delta12-PGJ2, may be an important contributor to neurodegeneration associated with accumulation of ubiquitinated proteins and inflammation.
authors.affiliation: Department of Biological Sciences, Hunter College of City University of New York, New York, NY 10021, USA.
authors.forename: Zongmin
authors.initials: Z
authors.lastname: Li
authors.forename: Francesco
authors.initials: F
authors.lastname: Melandri
authors.forename: Ingrid
authors.initials: I
authors.lastname: Berdo
authors.forename: Marlon
authors.initials: M
authors.lastname: Jansen
authors.forename: Lavonne
authors.initials: L
authors.lastname: Hunter
authors.forename: Saundrene
authors.initials: S
authors.lastname: Wright
authors.forename: Danielle
authors.initials: D
authors.lastname: Valbrun
authors.forename: Maria E
authors.initials: ME
authors.lastname: Figueiredo-Pereira
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D002478:Cells, Cultured; D003546:Cysteine Endopeptidases / Q000378:metabolism*; D015232:Dinoprostone / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000378:metabolism*; D007249:Inflammation / Q000378:metabolism; D051379:Mice; D015394:Molecular Structure; D009097:Multienzyme Complexes / Q000037:antagonists & inhibitors / Q000378:metabolism*; D009474:Neurons / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D015230:Prostaglandin D2 / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology*; D011454:Prostaglandins A / Q000737:chemistry / Q000494:pharmacology; D046988:Proteasome Endopeptidase Complex; D051381:Rats; D025801:Ubiquitin / Q000378:metabolism; D043222:Ubiquitin Thiolesterase / Q000037:antagonists & inhibitors / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D009097:Multienzyme Complexes; D011454:Prostaglandins A; D025801:Ubiquitin; C037112:9-deoxy-delta-9-prostaglandin D2; D043222:Ubiquitin Thiolesterase; D003546:Cysteine Endopeptidases; D046988:Proteasome Endopeptidase Complex; D015232:Dinoprostone; D015230:Prostaglandin D2; C100573:prostaglandin A1